Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

While children with comorbid conditions were at higher risk of RSV-hospitalisation, the importance of socio-demographic risk ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...